{
    "clinical_study": {
        "@rank": "70415", 
        "acronym": "PRISM II", 
        "arm_group": {
            "arm_group_label": "Nuedexta (DM 20 mg/Q 10 mg)", 
            "arm_group_type": "Other", 
            "description": "Single Arm, Open Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)"
        }, 
        "brief_summary": {
            "textblock": "The objectives of the study are to evaluate the safety, tolerability, and effectiveness of\n      NUEDEXTA capsules containing 20 mg DM (Dextromethorphan)/10 mg Q (Quinidine) for treatment\n      of PBA in patients with prevalent conditions such as  dementia, stroke and traumatic brain\n      injury over a 12 week period."
        }, 
        "brief_title": "Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pseudobulbar Affect (PBA)", 
            "Stroke", 
            "Dementia", 
            "Traumatic Brain Injury (TBI)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dementia", 
                "Stroke", 
                "Brain Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "This will be an Open-label, Multicenter, study in patients with PBA and dementia, stroke or\n      TBI. Patients with a clinical diagnosis of PBA and who meet all other inclusion and\n      exclusion criteria will be eligible to participate and receive NUEDEXTA for 12 weeks.\n\n      Males and females patients with a minimum age of 18 years, a clinical diagnosis of\n      Pseudobulbar Affect and a documented diagnosis of neurologic disease or brain injury, will\n      be enrolled in this study.\n\n      The primary effectiveness endpoint is the mean change in the CNS Lability scale (CNS-LS).\n      Secondary objectives include measures to evaluate treatment outcomes."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Center for Neurologic Study-Lability Scale (CNS-LS)score of 13 or greater\n\n          -  Clinical diagnosis of Pseudobulbar Affect (PBA)\n\n          -  Documentation of Neurologic disease or brain injury\n\n        Exclusion Criteria:\n\n          -  Unstable neurologic disease\n\n          -  Severe dementia\n\n          -  Stroke within 3 months\n\n          -  Penetrating TBI\n\n          -  Contraindications to Nuedexta\n\n          -  Severe Depressive Disorder"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "750", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01799941", 
            "org_study_id": "12-AVR-401"
        }, 
        "intervention": {
            "arm_group_label": "Nuedexta (DM 20 mg/Q 10 mg)", 
            "description": "Single Arm, Open-Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)", 
            "intervention_name": "Nuedexta (DM 20 mg/Q 10 mg)", 
            "intervention_type": "Drug", 
            "other_name": "Nuedexta"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Pensacola", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32503"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Study to Assess the Safety, Tolerability and Effectiveness of Nuedexta (Dextromethorphan 20 mg/Quinidine 10 mg) in the Treatment of Pseudobulbar Affect (PBA)", 
        "overall_contact": {
            "email": "pshin@avanir.com", 
            "last_name": "Fred Ledon", 
            "phone": "(949) 389-6724"
        }, 
        "overall_contact_backup": {
            "email": "pshin@avanir.com", 
            "last_name": "Paul Shin", 
            "phone": "(949) 268-5930"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The CNS-LS is a short (seven-item), self-administered questionnaire, designed to be completed by the patient or patient's caregiver, that provides a quantitative measure of the perceived frequency and severity of PBA episodes.", 
            "measure": "The primary efficacy endpoint is the mean change from baseline at 12 weeks in CNS-LS score.", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01799941"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assessments to include Patient History, Medication History,Concomitant Medication and Adverse Events.", 
                "measure": "Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "The PBA episode count is for the investigator to ask patient or patient's daytime caregiver to recall the PBA episodes.  The Patient or patient's caregiver will be instructed to identify, count and recall the average daily episodes of exaggerated/uncontrollable laughing or crying.", 
                "measure": "PBA Episode Counts", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "A 7-point (1-7) scale, where a patient/patient's caregiver assesses the patient's overall treatment response.", 
                "measure": "Patient Global Impression-Change (PGI-C)", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "description": "The CGI-C is a 7-point (1-7) scale and is an investigator-rated scale to assess the overall treatment response.", 
                "measure": "Clinical Global Impression-Change (CGI-C)", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "description": "The Patient treatment satisfaction survey is a 5 point single question survey that will be administered by the site staff to the patient/patient's caregiver.", 
                "measure": "Patient Satisfaction with Treatment Survey", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }
        ], 
        "source": "Avanir Pharmaceuticals", 
        "sponsors": {
            "collaborator": {
                "agency": "OptumInsight Life Sciences", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Avanir Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}